Xenon Pharmaceuticals Inc. (39) | Business Operations (6)
Browse by Subcategory
Recent Contracts
-
Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc
(Filed With SEC on March 1, 2022)
-
Amendment No. 1 to the At-the-Market Equity Offering Sales Agreement, dated March 1, 2022, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company,...
(Filed With SEC on March 1, 2022)
-
Termination Agreement, dated August 6, 2021, by and among Xenon Pharmaceuticals Inc., Genentech, Inc. and F. Hoffmann-La Roche Ltd
(Filed With SEC on August 11, 2021)
-
Amendment #1, dated January 13, 2021, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc
(Filed With SEC on January 14, 2021)
-
At-the-Market Equity Offering Sales Agreement dated as of August 6, 2020, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated
(Filed With SEC on August 6, 2020)
-
At-the-Market Equity Offering Sales Agreement dated as of November 5, 2019, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated
(Filed With SEC on November 5, 2019)
